Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

64 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-15

Study Completion Date

2024-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

NCT02695628

Adult Liver Carcinoma Liver Cirrhosis

COMPLETED PHASE2

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

NCT03303469

Hepatocellular Carcinoma

TERMINATED PHASE2

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

NCT00606294

Head and Neck Cancer

COMPLETED NA

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

NCT02016872

Non-Small-Cell-Lung Cancer (NSCLC)

COMPLETED NA

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

NCT01213030

Head and Neck Cancer Lung Cancer Liver Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radioembolization Radiotherapy Cancer Positron Emission Tomography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

Patients received radioembolization with hepatocellular cancer or colorectal cancer liver metastases

18F-Fluoromisonidazole PET

Intervention Type DIAGNOSTIC_TEST

Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-Fluoromisonidazole PET

Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with colorectal carcinoma with liver metastasis or hepatocellular carcinoma.
* Is not eligible for surgery
* Above 18 years old
* The patients who are referred for transarterial radioembolization treatment to Ankara University School of Medicine Department of Nuclear Medicine.